- Select a blog category
This week’s blog is written by our US colleague, Steve Burrill, who is the vice chairman and national sector leader for Deloitte’s Health Care Providers practice in the US. This article first appeared in My Take, part of Deloitte's Health Care Current platform.1 The article highlights some of the challenges of providing post-acute care and suggests a number of solutions, some of which may be pertinent to other healthcare systems, including ours here in the UK.
While discussions around Brexit took centre stage last week, it was also a significant week for awareness building in mental health, including mental health in the workplace. On Tuesday, the mental health charity Mind hosted their inaugural Workplace Wellbeing Index Awards, an event recognising and celebrating employers’ commitment to prioritising mental health at work. Two days later the ‘Heads Together’ campaign, aimed at championing awareness and addressing the stigma around mental health, launched a series of short films featuring celebrities and ordinary people describing life-changing conversations about their mental health.1 These events resonated strongly with us, as this week we are launching our new report At a tipping point? Workplace mental health and wellbeing. This week’s blog, by our colleague Elizabeth Hampson, explains the motivation behind our report and highlights some of its main findings.
Time to act?
Since the UK voted to leave the European Union (EU), some eight months ago, the ongoing debate has been dominated by uncertainty - with limited guidance on how to plan for changes to come. While there has been limited appetite to act in the context of such uncertainty, the Prime Minister’s decision to trigger Article 50 has now set the clock ticking.1
Since the UK’s vote to leave the EU, Deloitte have run a series of Brexit Labs to understand the implications of Brexit for the life sciences industry.2 This week’s blog highlights some of the insights identified, with some practical steps that could be taken in the coming months.
This week the House of Commons launched a ‘super inquiry‘ into the growing concern around air pollution in Britain. Four select committee panels will combine to examine the latest scientific evidence on how pollution in Britain is impacting health and the environment.1 This week’s blog is by our colleague, Giles Dean, a senior consultant in the firm’s risk advisory ractice; in it he discusses the impact that air pollution can have on our health and what is being done in the UK to tackle the problem.
Following a winter of media headlines that portrayed the NHS and social care as buckling under the strain of rising demand and difficulties in accessing services and support; last week’s Budget ended the speculation on how much additional funding would be available. While the inclusion of some immediate interventions aimed at lifting the NHS and social care out of their current predicament was welcomed, as the dust settles concerns are emerging from many quarters that the budget doesn’t go far or wide enough. This week’s blog explores the main budget proposals and what this means for social care and the NHS.
This week our colleague Sriram Prakash, Deloitte’s global lead for mergers and acquisitions (M&A) insight, published the cross industry M&A Index Outlook for 2017.1 This week’s blog draws on the report to explore the outlook for, and key drivers of, M&A in the Life Sciences industry in 2017.
This week’s blog is by our colleagues, Elisabeth Aloy and David Pistor, a Director and Senior Manager who specialise in life sciences and healthcare within the firms consulting practice in Switzerland. The article recently appeared in Scrip1 and outlines the five design principles that should be considered in order to create a successful value based care pilot.
This week’s blog is written by our research analyst Surbhi Mehta, who is based in the Deloitte India office in Hyderabad and has been working with the UK Centre for Health Solutions team for the past six months. The inspiration for her blog came from a Deloitte report India-UK Technology Collaborations- Smart cities, digital healthcare, advanced manufacturing and women in technology, launched in November 2016 at the India-UK Technology Summit. The focus of this blog is on how digital technology is transforming access to and the quality of healthcare in India.
Last week’s blog featured the Centre’s take on Deloitte’s recently published 2017 Global healthcare outlook; this week we are delighted to share with you a recent article by Greg Reh, Deloitte's global life sciences leader, on Deloitte’s 2017 Global life science outlook: Thriving in today’s uncertain market. This highlights the key challenges, trends and opportunities facing the global life science industry in 2017 and beyond and what is currently being done or could be done to respond to these challenges.
In January, Deloitte published its 2017 Global healthcare sector outlook, which confirms that the challenges of providing and funding health care around the globe have remained fairly persistent over the past few years, and they are unlikely to change in 2017. These, all too familiar challenges, comprise: rising demand and associated costs, growing prevalence of chronic diseases and comorbidities, development of costly clinical innovations; and increasing patient expectations and continued economic turbulence. While these challenges may appear somewhat intractable, green shoots of recovery are now being seen in some areas. This week’s blog highlights the key findings from the global healthcare sector report that we believe will resonate with our readers.
This week’s blog is written by our US colleague, Sonal Shah, a Senior Manager in our Deloitte US Center for Health Solutions and first appeared in A view from the Center, Deloitte's Life Sciences & Health Care Blog.1 Sonal worked closely with us on our recent report Balancing the R&D equation: Measuring the return from pharmaceutical innovation 2016, conducting interviews with pharmaceutical companies based in the US and deriving key insights for the report chapters on ‘Increasing pipeline value’ and ‘Reducing costs to launch’. Her blog considers the differences in interpretation that the main stakeholders might assign to the concept of value and how understanding and delivering against these different definitions of value, while challenging, will be necessary if drug innovation is to be sustained.